CTRI/2022/02/040430尚未招募未知
RANDOMISED, PLACEBO CONTROLED, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFECT OF TRIKATU IN SUBCLINICAL HYPOTHYROIDISM
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a.Patients of either sex with age between 18 and 60 years.
- •b.Freshly diagnosed Patients of subclinical Hypothyroidism with elevated TSH levels between 5.5-10uIU/ml with normal T4 value.
- •c.Patients, willing to give written informed consent to participate in the study
排除标准
- •a.TSH levels >10uIU/ml
- •b.Patients who have undergone any type of thyroid surgery.
- •c.Patients with uncontrolled Diabetes mellitus (HbA1C >8%).
- •d.Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT >3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.4 mg/dl)
- •e.Patients suffering from congenital hypothyroidism and secondary hypothyroidism.
- •f.Patients with poorly controlled hypertension ( >= 160/100 mmHg)
- •g.Patients who are under treatment for any thyroid disorder
- •h.Hypertensive patients who are on β blockers.
- •i.Symptomatic patients with clinical evidence of Heart failure.
- •j.Alcoholics and/or drug abusers.
- •k.H/o hypersensitivity to any of the trial drugs or their ingredients.
- •l.Pregnant/lactating woman.
- •m.Patients who are currently enrolled in any other clinical trial.
- •n.Any other condition which the Investigator thinks may jeopardize the study.
研究者
相似试验
已完成
2 期
Effect of Shilajit Rasayana compound in Diabetic Nerve DamageCTRI/2012/06/002712Institute for Post Graduate Teaching Research in Ayurveda60
进行中（未招募）
1 期
Trial treating brain injured patients with the anti-inflammatory drug Kineret: IL1ra-TBIWe wish to study the drug Kineret in patients suffering from moderate-to-severe traumatic brain injuryMedDRA version: 20.1Level: LLTClassification code 10060690Term: Traumatic brain injurySystem Organ Class: 100000004863MedDRA version: 20.1Level: PTClassification code 10051288Term: Central nervous system inflammationSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-004974-16-GBCambridge University Hospitals NHS Foundation Trust and the University of Cambridge60
进行中（未招募）
不适用
RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III, SUPERIORITY TRIAL TO ASSESS THE EFFICACY AND SAFETY OF ACETYL-L-CARNITINE IN COMBINATION WITH A CISPLATIN CONTAINING CHEMOTHERAPY AS FIRST LINE TREATMENT OF ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER - NDEUCTR2010-022021-15-ITIST. DI RICERCHE FARMACOLOG. M. NEGRI
进行中（未招募）
不适用
A randomised study comparing placebo and a not yet approved drug CS1008, in combination with drugs Carboplatin and Paclitaxel in patients with non small cell lung cancer which has spread or can not be removed by surgery, who have not had chemotherapy treatment before. The study is double-blind (that is when neither the patient nor the investigator know which treatment the patient is receiving).Treatment of metastatic or unresectable non small cell lung cancer (NSCLC) with CS 1008 or placebo first in combination with carboplatin/paclitaxel then as monotherapy in the first line settingMedDRA version: 14.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-004574-11-DEDaiichi Sankyo Development Limited120
已完成
不适用
SLV308 for Treatment of Patients With Early Parkinson´s Disease-G20 Parkinson´s diseaseParkinson´s diseaseG20PER-069-06SOLVAY PHARMACEUTICALS,